GSK provided an update on the CALM-1 and CALM-2 Phase III trials of camlipixant in adults with refractory chronic cough, noting that the aggregate results showed limited efficacy (with efficacy and safety assessed across two doses). The trial update is therefore a cautious development for the program, likely tempering expectations for the drug’s clinical value versus prior goals.
GSK provided an update on the CALM-1 and CALM-2 Phase III trials of camlipixant in adults with refractory chronic cough, noting that the aggregate results showed limited efficacy (with efficacy and safety assessed across two doses). The trial update is therefore a cautious development for the program, likely tempering expectations for the drug’s clinical value versus prior goals.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly negative
Sentiment Score
-0.25
Ticker Sentiment
